Permphan Dharmasaroja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Permphan Dharmasaroja has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Sombat Muengtaweepongsa
Center of Excellence in Stroke, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
11 shared publications Arvemas Watcharakorn
Stroke and Neurodegenerative Diseases Research Unit, Faculty of Medicine, Thammasat University, Klong 1, Klong Luang, Pathumthani 12120, Thailand
5 shared publications- Junya Pattaraarchachai
Chulabhorn International College of Medicine, Thammasat University, Khlong Luang district, Thailand
4 shared publications Kawinthra Khwanraj
Department of Anatomy, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
4 shared publicationsAthinan Prommahom
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand
3 shared publicationsPritsana Piyabhan
Department of Physiology, Faculty of Medicine, Thammasat University, Klong 1, Klong Luang, Pathumthani 12120, Thailand
3 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Korean Society of Medical Education in Korean Journal of Medical Education
- Vol. 38 (2) , 204-206
Integrating AI and digital medicine into undergraduate medical education
Korean Journal of Medical Education
- 1 June 2026
- Published by Korean Society of Medical Education in Korean Journal of Medical Education
- Vol. 38 (2) , 204-206
Open AccessIntegrating AI and digital medicine into undergraduate medical education
Korean Journal of Medical Education
- Open Access
- 1 January 2026
- Published by Wiley in The Scientific World Journal
- Vol. 2026 (1) , e4373377
The Multifaceted Roles of Eukaryotic Elongation Factor 1‐Alpha‐2 in Neurodevelopmental and Neurodegenerative Disorders
Eukaryotic elongation factor 1‐alpha‐2 (eEF1A2) is a neuron‐ and muscle‐specific translation elongation factor isoform that supports high‐demand proteostasis in terminally differentiated cells. Beyond its canonical role in translation elongation, eEF1A2 participates in noncanonical processes linked to actin cytoskeleton regulation, compartmentalized/local translation, and stress–response signaling. A central challenge in the field is that the strength and type of evidence implicating eEF1A2 differ substantially across disease classes. In neurodevelopmental disorders, heterozygous de novo pathogenic variants in EEF1A2 provide strong causal human genetic evidence for developmental and epileptic encephalopathies and related phenotypes, supported by functional studies showing reduced de novo protein synthesis/elongation and altered actin bundling in common patient‐associated variants. In contrast, in neurodegenerative paradigms (e.g., toxin‐based Parkinson′s disease models and ischemia‐reperfusion injury), eEF1A2 is primarily implicated as a contributory node within oxidative stress, autophagy/mitophagy, and inflammatory signaling pathways, largely based on cellular and animal model evidence rather than Mendelian causality. This review adopts an evidence‐based framework and organizes findings around a unified mechanistic model connecting canonical elongation and noncanonical cytoskeleton/stress/autophagy functions to neuronal phenotypes. Collectively, current evidence supports a causal role for eEF1A2 in neurodevelopmental disorders but only a contributory role in neurodegenerative conditions.
- 1 January 2026
- Published by Wiley in The Scientific World Journal
- Vol. 2026 (1) , e4373377
Open AccessThe Multifaceted Roles of Eukaryotic Elongation Factor 1‐Alpha‐2 in Neurodevelopmental and Neurodegenerative Disorders
Eukaryotic elongation factor 1‐alpha‐2 (eEF1A2) is a neuron‐ and muscle‐specific translation elongation factor isoform that supports high‐demand proteostasis in terminally differentiated cells. Beyond its canonical role in translation elongation, eEF1A2 participates in noncanonical processes linked to actin cytoskeleton regulation, compartmentalized/local translation, and stress–response signaling. A central challenge in the field is that the strength and type of evidence implicating eEF1A2 differ substantially across disease classes. In neurodevelopmental disorders, heterozygous de novo pathogenic variants in EEF1A2 provide strong causal human genetic evidence for developmental and epileptic encephalopathies and related phenotypes, supported by functional studies showing reduced de novo protein synthesis/elongation and altered actin bundling in common patient‐associated variants. In contrast, in neurodegenerative paradigms (e.g., toxin‐based Parkinson′s disease models and ischemia‐reperfusion injury), eEF1A2 is primarily implicated as a contributory node within oxidative stress, autophagy/mitophagy, and inflammatory signaling pathways, largely based on cellular and animal model evidence rather than Mendelian causality. This review adopts an evidence‐based framework and organizes findings around a unified mechanistic model connecting canonical elongation and noncanonical cytoskeleton/stress/autophagy functions to neuronal phenotypes. Collectively, current evidence supports a causal role for eEF1A2 in neurodevelopmental disorders but only a contributory role in neurodegenerative conditions.
- Open Access
- 20 March 2025
- Published by Elsevier in World Neurosurgery: X
- Vol. 26
Outcomes of patients with acute large anterior circulation vessel occlusion
- 20 March 2025
- Published by Elsevier in World Neurosurgery: X
- Vol. 26
Open AccessOutcomes of patients with acute large anterior circulation vessel occlusion
- 14 February 2025
- Published by Taylor & Francis in Medical Teacher
- Vol. 47 (9) , 1557-1558
Bridging the gaps in AI performance evaluation in medical education
- 14 February 2025
- Published by Taylor & Francis in Medical Teacher
- Vol. 47 (9) , 1557-1558
Bridging the gaps in AI performance evaluation in medical education
- Open Access
- 1 January 2025
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2025 (1)
Alpha‐Mangostin Alleviates Mitochondrial Damage and Autophagy Dysregulation in the MPP + Cellular Model of Parkinson’s Disease
Alpha‐mangostin (α‐M), a xanthone derivative with known antioxidative properties, has demonstrated a protective effect on neurons under oxidative stress, a key factor in the pathogenesis of Parkinson’s disease (PD). However, its impact on mitochondrial integrity and autophagy in PD remains insufficiently understood. Therefore, the present study aimed to investigate the role of α‐M in regulating defective mitochondrial proteins and its influence on the mTOR pathway, both of which are critical in the regulation of autophagy. This study investigated the effects of α‐M pretreatment on 1‐methyl‐4‐phenylpyridinium (MPP + )‐induced neurotoxicity in SH‐SY5Y dopaminergic neurons. MPP + , a mitochondrial complex I inhibitor, significantly reduced the expression of mitochondrial proteins NDUFS3 and TIMM23, induced mitochondrial damage, and triggered excessive autophagy, as evidenced by elevated LC3‐II/LC3‐I ratio and phospho‐Beclin‐1 expression. These changes were accompanied by dysregulation of the mTOR signaling pathway, including increased phosphorylation of mTOR and suppression of its downstream effector p70S6K. α‐M pretreatment restored NDUFS3 and TIMM23 levels, preserved mitochondrial morphology and membrane potential, and reduced autophagy activation by mitigating MPP + ‐induced LC3B accumulation and Beclin‐1 activation. Additionally, α‐M restored balance in the mTOR signaling pathway by reducing mTOR phosphorylation and restoring p70S6K activity, counteracting the autophagic dysregulation caused by MPP + . Importantly, α‐M exhibited no toxicity under normal conditions, indicating its protective effects are context‐dependent and activated only during cellular stress. These findings highlight the potential of α‐M as a therapeutic agent for PD, providing neuroprotection through its targeted modulation of mitochondrial proteins and mTOR signaling that regulates autophagy.
- 1 January 2025
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2025 (1)
Open AccessAlpha‐Mangostin Alleviates Mitochondrial Damage and Autophagy Dysregulation in the MPP + Cellular Model of Parkinson’s Disease
Alpha‐mangostin (α‐M), a xanthone derivative with known antioxidative properties, has demonstrated a protective effect on neurons under oxidative stress, a key factor in the pathogenesis of Parkinson’s disease (PD). However, its impact on mitochondrial integrity and autophagy in PD remains insufficiently understood. Therefore, the present study aimed to investigate the role of α‐M in regulating defective mitochondrial proteins and its influence on the mTOR pathway, both of which are critical in the regulation of autophagy. This study investigated the effects of α‐M pretreatment on 1‐methyl‐4‐phenylpyridinium (MPP + )‐induced neurotoxicity in SH‐SY5Y dopaminergic neurons. MPP + , a mitochondrial complex I inhibitor, significantly reduced the expression of mitochondrial proteins NDUFS3 and TIMM23, induced mitochondrial damage, and triggered excessive autophagy, as evidenced by elevated LC3‐II/LC3‐I ratio and phospho‐Beclin‐1 expression. These changes were accompanied by dysregulation of the mTOR signaling pathway, including increased phosphorylation of mTOR and suppression of its downstream effector p70S6K. α‐M pretreatment restored NDUFS3 and TIMM23 levels, preserved mitochondrial morphology and membrane potential, and reduced autophagy activation by mitigating MPP + ‐induced LC3B accumulation and Beclin‐1 activation. Additionally, α‐M restored balance in the mTOR signaling pathway by reducing mTOR phosphorylation and restoring p70S6K activity, counteracting the autophagic dysregulation caused by MPP + . Importantly, α‐M exhibited no toxicity under normal conditions, indicating its protective effects are context‐dependent and activated only during cellular stress. These findings highlight the potential of α‐M as a therapeutic agent for PD, providing neuroprotection through its targeted modulation of mitochondrial proteins and mTOR signaling that regulates autophagy.
- Open Access
- 1 January 2024
- Published by Medknow in Research in Pharmaceutical Sciences
- Vol. 19 (1) , 105-120
Moringa oleifera leaf extract suppresses TIMM23 and NDUFS3 expression and alleviates oxidative stress induced by Aβ1-42 in neuronal cells via activation of Akt
Background and purpose: Oxidative stress plays an important role in Alzheimer's disease (AD) pathogenesis. Moringa oleifera leaf (MOL) extract has been shown to have antioxidant activities. Here, we studied the antioxidative and anti-apoptotic effects of water-soluble MOL extract in an amyloid beta (Aβ)-induced oxidative stress model of AD. Experimental approach: The effect of amyloid beta (Aβ)1-42 and MOL extract on differentiated SH-SY5Y cell viability was assessed by MTT assay. Cells were treated with Aβ1-42, MOL extract, or MOL extract followed by Aβ1-42. The mitochondrial membrane potential (ΔΨm) and the reactive oxygen species (ROS) were evaluated by flow cytometry and dihydroethidium (DHE) assay, respectively. Western blotting was used to assess the expression of mitochondrial proteins TIMM23 and NDUFS3, apoptosis-related proteins Bax, Bcl-2, and cleaved caspase-3 along with fluorescence analysis of caspase-3/7, and Akt phosphorylation. Findings/Results: MOL extract pretreatment at 25, 50, and 100 μg/mL prevented ΔΨm reduction. At 100-μg/mL, MOL extract decreased TIMM23 and NDUFS3 proteins and DHE signals in Aβ1-42-treated cells. MOL extract pretreatment (25, 50, and 100 μg/mL) also alleviated the apoptosis indicators, including Bax, caspase-3/7 intensity, and cleaved caspase-3, and increased Bcl-2 levels in Aβ1-42-treated cells, consistent with a reduction in the number of apoptotic cells. The protective effects of MOL extract were possibly mediated through Akt activation, evidenced by increased Akt phosphorylation. Conclusion and implications: The neuroprotective effect of MOL extract could be mediated via the activation of Akt, leading to the suppression of oxidative stress and apoptosis in an Aβ1-42 model of AD.
- 1 January 2024
- Published by Medknow in Research in Pharmaceutical Sciences
- Vol. 19 (1) , 105-120
Open AccessMoringa oleifera leaf extract suppresses TIMM23 and NDUFS3 expression and alleviates oxidative stress induced by Aβ1-42 in neuronal cells via activation of Akt
Background and purpose: Oxidative stress plays an important role in Alzheimer's disease (AD) pathogenesis. Moringa oleifera leaf (MOL) extract has been shown to have antioxidant activities. Here, we studied the antioxidative and anti-apoptotic effects of water-soluble MOL extract in an amyloid beta (Aβ)-induced oxidative stress model of AD. Experimental approach: The effect of amyloid beta (Aβ)1-42 and MOL extract on differentiated SH-SY5Y cell viability was assessed by MTT assay. Cells were treated with Aβ1-42, MOL extract, or MOL extract followed by Aβ1-42. The mitochondrial membrane potential (ΔΨm) and the reactive oxygen species (ROS) were evaluated by flow cytometry and dihydroethidium (DHE) assay, respectively. Western blotting was used to assess the expression of mitochondrial proteins TIMM23 and NDUFS3, apoptosis-related proteins Bax, Bcl-2, and cleaved caspase-3 along with fluorescence analysis of caspase-3/7, and Akt phosphorylation. Findings/Results: MOL extract pretreatment at 25, 50, and 100 μg/mL prevented ΔΨm reduction. At 100-μg/mL, MOL extract decreased TIMM23 and NDUFS3 proteins and DHE signals in Aβ1-42-treated cells. MOL extract pretreatment (25, 50, and 100 μg/mL) also alleviated the apoptosis indicators, including Bax, caspase-3/7 intensity, and cleaved caspase-3, and increased Bcl-2 levels in Aβ1-42-treated cells, consistent with a reduction in the number of apoptotic cells. The protective effects of MOL extract were possibly mediated through Akt activation, evidenced by increased Akt phosphorylation. Conclusion and implications: The neuroprotective effect of MOL extract could be mediated via the activation of Akt, leading to the suppression of oxidative stress and apoptosis in an Aβ1-42 model of AD.
- Open Access
- 27 June 2023
- Published by Faculty of Medicine Ramathibodi Hospital, Mahidol University in Ramathibodi Medical Journal
- Vol. 46 (2) , 54-63
The Use of SOLO Taxonomy in Medical Education Training for Medical Teachers
Medical teachers need training in medical education to improve their teaching skills, keep up with modern teaching methods, and promote student-centered learning. Multiple methods exist for training medical teachers in the area of medical education. The SOLO (Structure of the Observed Learning Outcome) taxonomy can be included in training medical teachers. The SOLO taxonomy has five levels, which is used as a framework for assessing depth of understanding and the complexity of a learner’s response to a question. Here, the author constructed two questions in the field of medical education and provided examples of answers related to each level of understanding in the SOLO taxonomy. A medical educator can employ the SOLO taxonomy to conduct a qualitative analysis of the level of understanding of medical teachers and can use this understanding to design training activities that promote higher levels of thinking and understanding. Additionally, the SOLO taxonomy can be used to improve the effectiveness of training strategies, as well as to provide targeted feedback to medical teachers.
- 27 June 2023
- Published by Faculty of Medicine Ramathibodi Hospital, Mahidol University in Ramathibodi Medical Journal
- Vol. 46 (2) , 54-63
Open AccessThe Use of SOLO Taxonomy in Medical Education Training for Medical Teachers
Medical teachers need training in medical education to improve their teaching skills, keep up with modern teaching methods, and promote student-centered learning. Multiple methods exist for training medical teachers in the area of medical education. The SOLO (Structure of the Observed Learning Outcome) taxonomy can be included in training medical teachers. The SOLO taxonomy has five levels, which is used as a framework for assessing depth of understanding and the complexity of a learner’s response to a question. Here, the author constructed two questions in the field of medical education and provided examples of answers related to each level of understanding in the SOLO taxonomy. A medical educator can employ the SOLO taxonomy to conduct a qualitative analysis of the level of understanding of medical teachers and can use this understanding to design training activities that promote higher levels of thinking and understanding. Additionally, the SOLO taxonomy can be used to improve the effectiveness of training strategies, as well as to provide targeted feedback to medical teachers.
- Open Access
- 3 April 2023
- Published by Wiley in The Scientific World Journal
- Vol. 2023, 1-12
eEF1A2 siRNA Suppresses MPP+-Induced Activation of Akt and mTOR and Potentiates Caspase-3 Activation in a Parkinson’s Disease Model
The tissue-specific protein eEF1A2 has been linked to the development of neurological disorders. The role of eEF1A2 in the pathogenesis of Parkinsons disease (PD) has yet to be investigated. The aim of this study was to determine the potential neuroprotective effects of eEF1A2 in an MPP+ model of PD. Differentiated SH-SY5Y cells were transfected with eEF1A2 siRNA, followed by MPP+ exposure. The expression of p-Akt1 and p-mTORC1 was determined using Western blotting. The expression of p53, Bax, Bcl-2, and caspase-3 was evaluated using qRT-PCR. Cleaved caspase-3 levels and Annexin V/propidium iodide flow cytometry were used to determine apoptosis. The effects of PI3K inhibition were examined. The results showed that eEF1A2 siRNA significantly reduced the eEF1A2 expression induced by MPP+. MPP+ treatment activated Akt1 and mTORC1; however, eEF1A2 knockdown suppressed this activation. In eEF1A2-knockdown cells, MPP+ treatment increased the expression of p53 and caspase-3 mRNA levels as well as increased apoptotic cell death when compared to MPP+ treatment alone. In cells exposed to MPP+, upstream inhibition of the Akt/mTOR pathway, by either LY294002 or wortmannin, inhibited the phosphorylation of Akt1 and mTORC1. Both PI3K inhibitors increased eEF1A2 expression in cells, whether or not they were also treated with MPP+. In conclusion, eEF1A2 may function as a neuroprotective factor against MPP+, in part by regulating the Akt/mTOR pathway upstream.
- 3 April 2023
- Published by Wiley in The Scientific World Journal
- Vol. 2023, 1-12
Open AccesseEF1A2 siRNA Suppresses MPP+-Induced Activation of Akt and mTOR and Potentiates Caspase-3 Activation in a Parkinson’s Disease Model
The tissue-specific protein eEF1A2 has been linked to the development of neurological disorders. The role of eEF1A2 in the pathogenesis of Parkinsons disease (PD) has yet to be investigated. The aim of this study was to determine the potential neuroprotective effects of eEF1A2 in an MPP+ model of PD. Differentiated SH-SY5Y cells were transfected with eEF1A2 siRNA, followed by MPP+ exposure. The expression of p-Akt1 and p-mTORC1 was determined using Western blotting. The expression of p53, Bax, Bcl-2, and caspase-3 was evaluated using qRT-PCR. Cleaved caspase-3 levels and Annexin V/propidium iodide flow cytometry were used to determine apoptosis. The effects of PI3K inhibition were examined. The results showed that eEF1A2 siRNA significantly reduced the eEF1A2 expression induced by MPP+. MPP+ treatment activated Akt1 and mTORC1; however, eEF1A2 knockdown suppressed this activation. In eEF1A2-knockdown cells, MPP+ treatment increased the expression of p53 and caspase-3 mRNA levels as well as increased apoptotic cell death when compared to MPP+ treatment alone. In cells exposed to MPP+, upstream inhibition of the Akt/mTOR pathway, by either LY294002 or wortmannin, inhibited the phosphorylation of Akt1 and mTORC1. Both PI3K inhibitors increased eEF1A2 expression in cells, whether or not they were also treated with MPP+. In conclusion, eEF1A2 may function as a neuroprotective factor against MPP+, in part by regulating the Akt/mTOR pathway upstream.
- Open Access
- 22 February 2023
- Published by Springer Nature in Cureus
- Vol. 15 (2) , e35334
Episodic Headache, Periorbital Pain, and Multifocal Paresthesias as Presenting Symptoms of Central Neurocytoma: A Case Report
Central neurocytoma (CN) is a rare intraventricular tumor. The common presenting symptoms of CN are headache, vomiting, and visual disturbance, which results from increased intracranial pressure. This report presents a case of CN with unusual clinical presentations. A 25-year-old female with CN presented with a one-day history of unilateral headache, ipsilateral periorbital pain, multifocal paresthesias, and vomiting. Magnetic resonance images showed an intraventricular mass with a soap-bubble appearance and numerous cystic areas typical for CN, causing obstructive hydrocephalus and a midline shift. After one night of rest, her headache, periorbital pain, and paresthesias disappeared. It is possible that the tumor could be mobile with regard to the patient's head position, causing occasional obstruction of the foramen of Monro. Due to the tumor size, which was larger than 4 centimeters, the surgical approach with either gross tumor resection or subtotal resection plus adjuvant radiotherapy should be carefully considered.
- 22 February 2023
- Published by Springer Nature in Cureus
- Vol. 15 (2) , e35334
Open AccessEpisodic Headache, Periorbital Pain, and Multifocal Paresthesias as Presenting Symptoms of Central Neurocytoma: A Case Report
Central neurocytoma (CN) is a rare intraventricular tumor. The common presenting symptoms of CN are headache, vomiting, and visual disturbance, which results from increased intracranial pressure. This report presents a case of CN with unusual clinical presentations. A 25-year-old female with CN presented with a one-day history of unilateral headache, ipsilateral periorbital pain, multifocal paresthesias, and vomiting. Magnetic resonance images showed an intraventricular mass with a soap-bubble appearance and numerous cystic areas typical for CN, causing obstructive hydrocephalus and a midline shift. After one night of rest, her headache, periorbital pain, and paresthesias disappeared. It is possible that the tumor could be mobile with regard to the patient's head position, causing occasional obstruction of the foramen of Monro. Due to the tumor size, which was larger than 4 centimeters, the surgical approach with either gross tumor resection or subtotal resection plus adjuvant radiotherapy should be carefully considered.
- Open Access
- 16 January 2023
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2023, 1-8
Evaluation of the Combination of Metformin and Rapamycin in an MPP+-Treated SH-SY5Y Model of Parkinson’s Disease
Metformin (MET) and rapamycin (RAPA) have been reported to protect against neurodegeneration in cellular and animal models of Parkinsons disease (PD). MET, which is a first-line drug for type 2 diabetes, and RAPA are known as mTORC1 inhibitors. MET also acts as an AMPK activator, which leads to the inhibition of mTORC1 activity. mTORC1 is a downstream target of Akt signaling. Inactivation of Akt/mTORC1 and its downstream S6K1 can promote autophagy, a process involved in PD pathogenesis. Based on their mechanisms and potential benefits, we evaluated the potential protective effect of pretreatment with combinations of MET and RAPA in a 1-methyl-4-phenylpyridinium ion (MPP+)-treated SH-SY5Y neuronal cell model of PD. The results showed that MET and RAPA combinations lowered cell viability after exposure to MPP+. Increased LC3-II levels by MPP+ were not altered by MET and RAPA pretreatment. In normal neuronal cells, MET and RAPA pretreatment inhibited the phosphorylation of both Akt and S6K1, and the phosphorylation remained suppressed after MPP+ exposure. These findings suggest that when cells were exposed to MPP+, suppressed phosphorylation of both Akt and S6K1 by the MET and RAPA combination may lead to an inappropriate autophagic response, resulting in increased cell death.
- 16 January 2023
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2023, 1-8
Open AccessEvaluation of the Combination of Metformin and Rapamycin in an MPP+-Treated SH-SY5Y Model of Parkinson’s Disease
Metformin (MET) and rapamycin (RAPA) have been reported to protect against neurodegeneration in cellular and animal models of Parkinsons disease (PD). MET, which is a first-line drug for type 2 diabetes, and RAPA are known as mTORC1 inhibitors. MET also acts as an AMPK activator, which leads to the inhibition of mTORC1 activity. mTORC1 is a downstream target of Akt signaling. Inactivation of Akt/mTORC1 and its downstream S6K1 can promote autophagy, a process involved in PD pathogenesis. Based on their mechanisms and potential benefits, we evaluated the potential protective effect of pretreatment with combinations of MET and RAPA in a 1-methyl-4-phenylpyridinium ion (MPP+)-treated SH-SY5Y neuronal cell model of PD. The results showed that MET and RAPA combinations lowered cell viability after exposure to MPP+. Increased LC3-II levels by MPP+ were not altered by MET and RAPA pretreatment. In normal neuronal cells, MET and RAPA pretreatment inhibited the phosphorylation of both Akt and S6K1, and the phosphorylation remained suppressed after MPP+ exposure. These findings suggest that when cells were exposed to MPP+, suppressed phosphorylation of both Akt and S6K1 by the MET and RAPA combination may lead to an inappropriate autophagic response, resulting in increased cell death.